Medicines and healthcare products regulatory agency (mhra) authorizes moderna's omicron-containing bivalent booster in the uk

Study results show mrna-1273.214 has demonstrated significantly higher antibody titers against omicron ba.1 and ba.4/5 subvariants when compared with mrna-1273 cambridge, ma / accesswire / august 15, 2022 / moderna, inc . (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that the medicines and healthcare products regulatory agency (mhra) in the uk has granted conditional authorization for the use of the omicron-containing bivalent covid-19 booster vaccine, mrna-1273.214 (spikevax bivalent original/omicron▼) as a booster dose for active immunization to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older.
MRNA Ratings Summary
MRNA Quant Ranking